Leuva, H., Zhou, M., Jamaleddine, N., Meseha, M., Faiena, I., Anna Park, Y.-H., McWilliams, G., Luhrs, C., Maxwell, K. N., Von Hoff, D., Bates, S. E., & Fojo, T. (2024). Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent -rate method ideal for real-world analyses. EBioMedicine, 107, 105288. https://doi.org/10.1016/j.ebiom.2024.105288

Tai, Y., Chow, A., Han, S., Coker, C., Ma, W., Gu, Y., Estrada Navarro, V., Kandpal, M., Hibshoosh, H., Kalinsky, K., Manova-Todorova, K., Safonov, A., Walsh, E. M., Robson, M., Norton, L., Baer, R., Merghoub, T., Biswas, A. K., & Acharyya, S. (2024). FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Molecular Medicine, 16(8), 1957–1980. https://doi.org/10.1038/s44321-024-00094-2

Kline, C., Crawford, J. R., Reddy, A. T., Gerber, N., Stucklin, A. G., Kilburn, L., Packer, R., Margol, A., Crotty, E., Sayour, E., Franson, A., Phillips, J., Singh, S., Hamanishi, E., Lee, C., Bhatia, A., George, E., Rauschecker, A., Molinaro, A., … Mueller, S. (2024). TRLS-07. PNOC016: INTRATUMORAL PHARMACOKINETICS AND PHARMACODYNAMIC (PK/PD) RESULTS FROM A TARGET VALIDATION STUDY OF A NOVEL PAN-HDAC AND PI3K INHIBITOR, FIMEPINOSTAT, IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG), RECURRENT MEDULLOBLASTOMA (MB), AND RECURRENT HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.160

Carmichael, J., Figueiredo, I., Gurel, B., Beije, N., Yuan, W., Rekowski, J., Seed, G., Carreira, S., Bertan, C., Fenor de la Maza, M. de L. D., Chandran, K., Neeb, A., Welti, J., Gallagher, L., Bogdan, D., Crespo, M., Riisnaes, R., Ferreira, A., Miranda, S., … de Bono, J. (2024). RNASEH2B loss and PARP inhibition in advanced prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci178278

Fojo, T., LaRose, M., & Bates, S. E. (2024). The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype. The Oncologist, 29(4), 275–277. https://doi.org/10.1093/oncolo/oyae042

Nemzow, L., Boehringer, T., Bacon, B., & Turner, H. C. (2023). Development of a human peripheral blood ex vivo model for rapid protein biomarker detection and applications to radiation biodosimetry. PLOS ONE, 18(8), e0289634. https://doi.org/10.1371/journal.pone.0289634

Shao, Z., Lee, B. J., Zhang, H., Lin, X., Li, C., Jiang, W., Chirathivat, N., Gershik, S., Shen, M. M., Baer, R., & Zha, S. (2023). Inactive PARP1 causes embryonic lethality and genome instability in a dominant-negative manner. Proceedings of the National Academy of Sciences, 120(31). https://doi.org/10.1073/pnas.2301972120

Schvartzman, J.-M., Forsyth, G., Walch, H., Chatila, W., Taglialatela, A., Lee, B. J., Zhu, X., Gershik, S., Cimino, F. V., Santella, A., Menghrajani, K., Ciccia, A., Koche, R., Sánchez-Vega, F., Zha, S., & Thompson, C. B. (2023). Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Molecular Cell, 83(13), 2347-2356.e8. https://doi.org/10.1016/j.molcel.2023.05.026

Kimble, M. T., Johnson, M. J., Nester, M. R., & Symington, L. S. (2023). Long-range DNA end resection supports homologous recombination by checkpoint activation rather than extensive homology generation. ELife, 12. CLOCKSS. https://doi.org/10.7554/elife.84322

LaRose, M., Connolly, R. M., O’Sullivan, C. C., Velcheti, V., Vilimas, R., Gano, K., Bates, S. E., Pommier, Y., & Thomas, A. (2023). A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. The Oncologist, 28(5), 460-e298. https://doi.org/10.1093/oncolo/oyad023

Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R. M., Ross, A., Mills, M., Suarez, C. J., Davis, T., Edwards, R., Boisen, M., Sawyer, S., Wu, H.-T., Dashner, S., Aushev, V. N., George, G. V., Malhotra, M., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology, 167(2), 334–341. https://doi.org/10.1016/j.ygyno.2022.09.004

Wang, Z., Wang, J., Zhao, H., Zhao, T., Chen, Y., Jiang, M., Zhang, S., Wei, Y., Zhang, J., Zhou, Y., Shi, S., Fu, Z., Yang, Y., Zhang, Y., Yang, L., Que, J., & Liu, K. (2022). Targeting the SOX2/PARP1 complex to intervene in the growth of esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy, 153, 113309. https://doi.org/10.1016/j.biopha.2022.113309

Park, D., Gharghabi, M., Reczek, C. R., Plow, R., Yungvirt, C., Aldaz, C. M., & Huebner, K. (2022). Wwox Binding to the Murine Brca1-BRCT Domain Regulates Timing of Brip1 and CtIP Phospho-Protein Interactions with This Domain at DNA Double-Strand Breaks, and Repair Pathway Choice. International Journal of Molecular Sciences, 23(7), 3729. https://doi.org/10.3390/ijms23073729